Moleculin Biotech Inc. (MBRX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, MBRX scores 34 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillars are the cash engine and the two flow-based pillars, each scoring 25% or less of its maximum. For a prospective investor, this profile points to a company that is not currently generating cash from operations, with negative returns on invested capital and no free-cash-flow yield to support valuation. The balance sheet metrics sit in a middling range rather than a distressed one, but the rating framework weights the absence of operating cash generation heavily. Upside would depend on factors outside the reported operating figures, and the source data does not establish a path to earnings or cash-flow inflection. This is an analytical reading of the rating, not a recommendation.

Per the SEC financials, operating losses narrowed from $-29.6M in FY 2023 to $-25.1M in FY 2025, while reported net income was positive in each period ($29.8M, $26.0M, $33.6M), a divergence from operating results that the source data does not explain. Gross, operating, and net margins are each 0% per the market data section, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash rose from $4.3M to $8.9M over the period, while free cash flow remained negative in every year presented.

Per the recent news and catalysts section, six items were published within roughly the prior 15 hours and are all tagged YELLOW under the impact label MARKET WIRE. The headlines reference a 1-for-20 reverse stock split announced amid a market selloff (per GuruFocus) and a separate reverse split announcement (per GlobeNewswire), as well as a Stock Titan item noting that half of the CFO's stock awards vest on grant. Several other items are generic quote or profile pages from Yahoo Finance, CNN, and Yahoo Finance Canada. Risk watch items include the reverse split activity and the sharp gap between the 52-week low of $3.13 and high of $106, which the source data does not reconcile. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE with no butterfly links and no proprietary signals.

• What is the source of reported net income of $33.6M in FY 2025 given operating losses of $-25.1M and zero revenue?
• What products, clinical programs, or revenue arrangements underlie the company, and what is its pipeline status?
• What do the reverse stock split announcements imply for share count, listing compliance, and dilution?
• Why does the 52-week range span from $3.13 to $106, and which price history is correct?
• What is the company's current debt position, since debt is reported as N/A in every period?